Latest News & Features
Americas
In the high stakes world of life sciences, the strength of a company’s IP portfolio can determine the value of a corporate transaction, argue Jonathan Harris and Nisan Zaghi of Axinn, and Ian Lodovice of Biogen. 9 July 2020
Europe
Drug company Teva has lost an appeal over its bid to trademark two word signs, after the tenth chamber of the EU General Court ruled in favour of the European Union IP Office (EUIPO) yesterday, July 8. 9 July 2020
article
Amid confusion over patent eligibility, US life sciences IP owners should consider trade secret law when building their IP protection strategy, argues John A Stone of DeCotiis, FitzPatrick, Cole & Giblin. 9 July 2020
Biotechnology
A Roche subsidiary will be unable to block Amgen from producing the cancer drug Mvasi (bevacizumab), the Court of Appeals for the Federal Circuit has ruled. 7 July 2020
article
Jakob Wested is currently working on repurposing of medicine with Johnathan Liddicoat from Cambridge which has some interesting perspectives around the current COVID situation. Jakob's contribution will touch upon issues of patenting second medical use as well as the complementarity between IPR and regulatory exclusivities. 7 July 2020
Europe
The European Patent Office has unveiled data sets relating to antiviral vaccines and pharmaceutical therapeutics as part of its new “Fighting coronavirus” platform. 6 July 2020
Asia-Pacific
The Federal Court of Australia has upheld a patent victory for Indian generic manufacturer Sun Pharma over Mylan in a dispute over cholesterol drug fenofibrate. 6 July 2020
Big Pharma
US medical technology company CardioNet has lost an appeal at the US Court of Appeals for the Federal Circuit , which found its patents covered abstract concepts and therefore are invalid. 3 July 2020
Big Pharma
European law firm Carpmaels & Ransford has promoted Jennifer Antcliff to partner in its dispute resolution team in its London office, bringing the total number of partners in the team to five. 2 July 2020
Americas
Amgen has won a key patent victory over Sandoz in a dispute over biologic Enbrel. 2 July 2020